Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats

Kidney and Blood Pressure Research

Volumn 31, Issue 5, 2008, Pages 350-359

  Waanders, Femke ^a   Van Goor, Harry ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adriamycin nephrosis; Advanced glycation end products; Hypercholesterolemia; Maillard reaction; Proteinuria; Renin angiotensin aldosterone system

Indexed keywords

DOXORUBICIN; LISINOPRIL; PYRIDOXAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; HYPERCHOLESTEROLEMIA; KIDNEY INJURY; LIPID STORAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; DOXORUBICIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY DISEASES; LIPIDS; LISINOPRIL; PROTEINURIA; PYRIDOXAMINE; RATS;

EID: 56149092874     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173253     Document Type: Article

References (38)

1. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001;38:S100-S106.
2. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656-1666.
3. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H: Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995;44:824-829.
4. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-950.
5. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328-1334.
6. Zheng F, Zeng YJ, Plati AR, Elliot SJ, Berho M, Potier M, Striker LJ, Striker GE: Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 2006;70:507-514.
7. Waanders F, van den Berg E, Nagai R, van Veen I, Navis G, Van Goor H: Renoprotective effects of the AGE inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats. Nephrol Dial Transplant 2008;23:518-524.
8. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003;63:2123-2133.
9. Greven WL, Waanders F, Nagai R, van den Heuvel MC, Navis G, Van Goor H: Mesangial accumulation of GA-pyridine, a novel glycolaldehyde-derived AGE, in human renal disease. Kidney Int 2005;68:595-602.
10. Waanders F, Greven WL, Baynes JW, Thorpe SR, Kramer AB, Nagai R, Sakata N, Van Goor H, Navis G: Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats. Nephrol Dial Transplant 2005;20:2060-2070.
11. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A: Advanced glycation end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 1999;25:380-383.
12. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-11708.
13. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M: Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. Kidney Int 2003;63:464-473.
14. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994;45:S174-S178.
15. De Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S: Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 2006;69:1675-1682.
16. Navis G, de Zeeuw D: Titrating for antiproteinuric effect: the clue to renoprotection? J Hum Hypertens 1996;10:669-673.
17. Smit-van Oosten A, Navis G, Stegeman CA, Joles JA, Klok PA, Kuipers F, Tiebosch AT, Van Goor H: Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J Pathol 2001;194: 122-129.
18. Cushman DW, Cheung HS: Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta 1971;250:261-265.
19. Metz TO, Alderson NL, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003;419:41-49.
20. Davis BJ, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H, Allen TJ, Cooper ME: Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2004;47:89-97.
21. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, Arnstein M, Thorpe SR, Cooper ME, Forbes JM: Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin-converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 2007;148:886-895.
22. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit-Dahm K, Cooper ME, Forbes JM: Interactions between renin-angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-2984.
23. Alderson NL, Chachich ME, Frizzell N, Canning P, Metz TO, Januszewski AS, Youssef NN, Stitt AW, Baynes JW, Thorpe SR: Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 2004;47:1385-1395.
24. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002;51:2826-2832.
25. Wapstra FH, van Goor H, de Jong PE, Navis G, de Zeeuw D: Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. J Pharmacol Toxicol Methods 1999;41:69-73.
26. Bidani AK, Griffin KA: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004;44:595-601.
27. Mittman N, Avram MM: Dyslipidemia in renal disease. Semin Nephrol 1996;16:202-213.
28. Moorhead JF, Chan MK, El Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;ii:1309-1311.
29. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J: Early events leading to renal injury in obese Zucker (fatty) rats with type 2 diabetes. Kidney Int 2000;57:167-182.
30. Fujihara CK, Padilha RM, Zatz R: Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy. Diabetes 1992;41:286-293.
31. Lee HS, Lee JS, Koh HI, Ko KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991;36:67-75.
32. Saito K, Ishizaka N, Hara M, Matsuzaki G, Sata M, Mori I, Ohno M, Nagai R: Lipid accumulation and transforming growth factor-β upregulation in the kidneys of rats administered angiotensin II. Hypertension 2005;46:1180-1185.
33. Parry GJ, Bredesen DE: Sensory neuropathy with low-dose pyridoxine. Neurology 1985;35:1466-1468.
34. Cohen M, Bendich A: Safety of pyridoxine - a review of human and animal studies. Toxicol Lett 1986;34:129-139.
35. 6) toxicity: enhancement by uremia in rats. Food Chem Toxicol 2002;40:1449-1451.
36. 6) neurotoxicity: enhancement by protein-deficient diet. J Appl Toxicol 2004;24:497-500.
37. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27:605-614.
38. Voziyan PA, Hudson BG: Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005;62:1671-1681.